| PubMed | Title | Journal | Year | Linked by |
|---|
| PMID 41422765 | Urothelial Carcinoma In Situ: Advances in Diagnosis and Management. | Clinical genitourinary cancer | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 41555169 | [Evolving Pharmacotherapy for Bladder Cancer-From Non-Muscle-Invasive to Metastatic Disease-Development of Novel Therapies for BCG-Unresponsive NMIBC]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 41647170 | Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics. | Molecular therapy. Oncology | 2026 | name in abstract: Adstiladrin |
| PMID 41749876 | Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer. | Cancers | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 41780023 | Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy. | Journal of medical economics | 2026 | name in title: nadofaragene firadenovec |
| PMID 41825577 | Advances in intravesical therapy for non-muscle-invasive bladder cancer. | Critical reviews in oncology/hematology | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 42012856 | Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States. | Journal of medical economics | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 42216552 | Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer. | Frontiers in bioscience (Landmark edition) | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 42248643 | Non-replicating adenoviral vectors for cancer gene therapy. | Advances in cancer research | 2026 | name in abstract: Adstiladrin |
| PMID 42260513 | Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances. | BMC urology | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 42293862 | Analysis of real-world re-induction outcomes with nadofaragene firadenovec in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer. | Translational andrology and urology | 2026 | name in title: nadofaragene firadenovec |
| PMID 42362299 | Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer. | The Urologic clinics of North America | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 42599325 | Deep learning-based automated identification of papillary bladder cancer from endoscopic still images using SE-ResNeXt-50. | World journal of urology | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 42702389 | [Advances in intravesical therapy for non-muscle-invasive bladder cancer]. | Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 42729065 | Re-induction with nadofaragene firadenovec: a fragile signal that should not influence clinical practice. | Translational andrology and urology | 2026 | name in title: nadofaragene firadenovec |
| PMID 42792838 | Molecular Classifications and Candidate Biomarkers for Personalizing BCG Therapy in Non-Muscle-Invasive Bladder Cancer. | Biomedicines | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 42798234 | Trial design drives outcomes: harmonising efficacy across BCG-unresponsive bladder carcinoma in situ trials. | BJU international | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 42823172 | Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS. | Anticancer research | 2026 | name in title: nadofaragene firadenovec |
| PMID 42881230 | Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies. | Nature reviews. Urology | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 42967132 | Bladder-Sparing Therapies for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ: An Upper and a Lower Response Group With an Unstable Boundary. | Cureus | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 42991509 | Defining safe bladder preservation in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: beyond complete response. | Frontiers in immunology | 2026 | name in abstract: nadofaragene firadenovec |
| PMID 39376040 | Novel intravesical therapies and delivery systems for the management of bladder cancer. | Current opinion in urology | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 39550339 | Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group. | European urology oncology | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 39705065 | FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | name in title: nadofaragene firadenovec-vncg |
| PMID 39779686 | Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. | Expert opinion on biological therapy | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 39933135 | New Treatment Options for Non-Muscle-Invasive Bladder Cancer. | American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 39962875 | Practical use of nadofaragene firadenovec-vncg for pharmacists. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2025 | name in title: nadofaragene firadenovec-vncg |
| PMID 39976835 | Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer. | Current oncology reports | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 40396643 | Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer, a study with 5-year follow-up: a plain language summary. | Future oncology (London, England) | 2025 | name in title: nadofaragene firadenovec |
| PMID 40569326 | Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer. | The Journal of urology | 2025 | name in title: nadofaragene firadenovec |
| PMID 40584211 | Emerging bladder-sparing treatments for high risk non-muscle invasive bladder cancer. | Bladder cancer (Amsterdam, Netherlands) | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 40635630 | Intravesical interferon-α2b gene therapy with nadofaragene firadenovec-vncg: a contemporary review. | Future oncology (London, England) | 2025 | name in title: nadofaragene firadenovec-vncg |
| PMID 40697667 | Advancements in bladder cancer immunotherapy: a focus on intravesical approaches. | Frontiers in pharmacology | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 40852908 | Outcomes of Reinduction With Nadofaragene Firadenovec. | The Journal of urology | 2025 | name in title: nadofaragene firadenovec |
| PMID 40932192 | [INNOVATIONS IN THERAPIES FOR BACILLUS CALMETTE-GUERIN (BCG) FAILURE NON-MUSCLE INVASIVE PATIENTS]. | Harefuah | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 40948378 | Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer. | Cancer medicine | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 40970394 | Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation. | Current opinion in urology | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 41230142 | Pharmacotherapy for bladder spasm and irritative lower urinary tract symptoms associated with intravesical therapy for bladder cancer: a review of available evidence. | Translational andrology and urology | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 41300998 | Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions. | Cancers | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 41396440 | A systematic review of gene-mediated therapy in BCG-unresponsive NMIBC: emerging evidence and future perspectives. | World journal of urology | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 41425090 | Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies. | Frontiers in cell and developmental biology | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 41496691 | A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania. | Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica | 2025 | name in abstract: nadofaragene firadenovec |
| PMID 38559556 | Mechanism of action of nadofaragene firadenovec-vncg. | Frontiers in oncology | 2024 | name in title: nadofaragene firadenovec-vncg |
| PMID 38611044 | Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. | Cancers | 2024 | name in abstract: nadofaragene firadenovec |
| PMID 38849286 | Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer. | European urology oncology | 2024 | name in abstract: nadofaragene firadenovec |
| PMID 38861054 | An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer. | Expert opinion on biological therapy | 2024 | name in title: nadofaragene firadenovec-vncg |
| PMID 38886756 | Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment. | Journal of experimental & clinical cancer research : CR | 2024 | name in abstract: nadofaragene firadenovec |
| PMID 38895918 | Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. | The Journal of urology | 2024 | name in title: nadofaragene firadenovec |
| PMID 38912644 | Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. | The Journal of urology | 2024 | name in title: nadofaragene firadenovec |
| PMID 38968037 | Reply: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. | The Journal of urology | 2024 | name in title: nadofaragene firadenovec |
| PMID 39131870 | The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward. | Bladder cancer (Amsterdam, Netherlands) | 2024 | name in title: nadofaragene firadenovec |
| PMID 39183090 | Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. | European urology | 2024 | name in abstract: nadofaragene firadenovec |
| PMID 39254130 | Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. | The Journal of urology | 2024 | name in title: nadofaragene firadenovec |
| PMID 39315392 | Clinical use of nadofaragene firadenovec-vncg. | Therapeutic advances in urology | 2024 | name in title: nadofaragene firadenovec-vncg |
| PMID 39339191 | Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024. | Pharmaceutics | 2024 | name in abstract: Adstiladrin |
| PMID 39552770 | Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC): Current Guidance and Experience from Clinical Practice. | Research and reports in urology | 2024 | name in abstract: nadofaragene firadenovec |
| PMID 39559365 | Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model. | Frontiers in immunology | 2024 | name in abstract: nadofaragene firadenovec |
| PMID 36529422 | Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non-Muscle Invasive Bladder Cancer. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2023 | name in title: nadofaragene firadenovec |
| PMID 36856952 | Nadofaragene Firadenovec: First Approval. | Drugs | 2023 | name in title: nadofaragene firadenovec |
| PMID 36877284 | In brief: Adstiladrin - a gene therapy for bladder cancer. | The Medical letter on drugs and therapeutics | 2023 | name in title: Adstiladrin |
| PMID 37269456 | Correction to: Nadofaragene Firadenovec: First Approval. | Drugs | 2023 | name in title: nadofaragene firadenovec |
| PMID 37705979 | Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval. | Frontiers in immunology | 2023 | name in title: nadofaragene firadenovec |
| PMID 38037752 | Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer. | Cancer medicine | 2023 | name in abstract: nadofaragene firadenovec-vncg |
| PMID 38993180 | New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer. | Bladder cancer (Amsterdam, Netherlands) | 2023 | name in abstract: nadofaragene firadenovec |
| PMID 40778028 | Nadofaragene firadenovec: a breakthrough in the field of bladder oncology. | Frontiers in urology | 2023 | name in title: nadofaragene firadenovec |
| PMID 35086977 | Emerging treatment options for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer. | Current opinion in supportive and palliative care | 2022 | name in abstract: nadofaragene firadenovec |
| PMID 35158964 | From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC). | Cancers | 2022 | name in abstract: nadofaragene firadenovec |
| PMID 35172349 | [Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond BCG and mitomycin C]. | Aktuelle Urologie | 2022 | name in abstract: nadofaragene firadenovec |
| PMID 35383434 | Do we have enough evidence for approval of nadofaragene firadenovec? | Minerva urology and nephrology | 2022 | name in title: nadofaragene firadenovec |
| PMID 35634893 | Emerging treatment landscape of non-muscle invasive bladder cancer. | Expert opinion on biological therapy | 2022 | name in abstract: nadofaragene firadenovec |
| PMID 36051251 | Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments. | Archives of pharmacology and therapeutics | 2022 | name in abstract: nadofaragene firadenovec |
| PMID 33253640 | Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer? | The Lancet. Oncology | 2021 | name in title: nadofaragene firadenovec |
| PMID 33551296 | Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial. | European urology | 2021 | name in title: nadofaragene firadenovec |
| PMID 33622578 | Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial. | European urology | 2021 | name in title: nadofaragene firadenovec |
| PMID 33742981 | The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer. | Current opinion in urology | 2021 | name in abstract: nadofaragene firadenovec |
| PMID 33958148 | Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer. | Hematology/oncology clinics of North America | 2021 | name in abstract: nadofaragene firadenovec |
| PMID 34057394 | The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer. | Journal of managed care & specialty pharmacy | 2021 | name in title: nadofaragene firadenovec |
| PMID 34709440 | [Bacillus Calmette-Guérin (BCG) and alternatives : Drug treatment of high-risk non-muscle invasive bladder cancer]. | Der Urologe. Ausg. A | 2021 | name in abstract: nadofaragene firadenovec |
| PMID 34938855 | Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance. | Molecular therapy oncolytics | 2021 | name in abstract: nadofaragene firadenovec |
| PMID 32304379 | Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected? | Current opinion in urology | 2020 | name in abstract: rAd-IFN/Syn3 |
| PMID 32427633 | Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer. | Current opinion in urology | 2020 | name in abstract: Adstiladrin |
| PMID 30357541 | Current Clinical Trials in Non-muscle Invasive Bladder Cancer. | Current urology reports | 2018 | name in abstract: nadofaragene firadenovec |
| PMID 21900961 | Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys. | Gene therapy | 2012 | name in abstract: SCH 721015 |
| PMID 17692556 | Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. | Cytokine & growth factor reviews | 2007 | name in abstract: rAd-IFN/Syn3 |
| PMID 15992886 | Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. | Urology | 2005 | name in abstract: rAd-IFN/Syn3 |